Ying Cheng

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 456 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · JAMA · 2018 · 404 citations · Full text

Medicine, Oncology, Pharmacology +17

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab

Jingjing Liu, Shuang Li, Shuang Zhang et al. · Journal of Clinical Laboratory Analysis · 2019 · 370 citations · Full text

Life Sciences, Immunology, Oncology +17

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding, Jia Fan, Do‐Youn Oh et al. · The Lancet Oncology · 2023 · 247 citations · Full text

Medicine, Oncology, Pharmacology +10